Breaking News

Baxter BioScience Names R&D VP

July 10, 2014

Orloff to head pipeline innovation

John Orloff, M.D., has been appointed vice president and global head of R&D for Baxter BioScience. Dr. Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional opportunities for the business.
Dr. Orloff joins the company from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Previously, he spent 10 years at Novartis, where he served various roles of increasing responsibility, including chief medical officer for global development. Dr. Orloff also supported clinical development at Merck Research Labs. Dr. Orloff brings expertise in bone biology, and has led programs across a range of therapeutic areas, including immunology, neurology and oncology.
“As we work toward becoming an independent global biopharmaceutical company, our priorities are to drive innovation by advancing our rich, late-stage development pipeline, expanding our expertise in immunology, hematology, and other core technologies and optimizing our R&D productivity,” said Ludwig Hantson, Ph.D., president of Baxter BioScience. “John brings significant scientific and leadership expertise, including preclinical research, clinical development, and medical and regulatory affairs. He will be a valuable member of our executive leadership team and a guiding force for effectively executing the development strategy for our organization.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity